Amphastar Pharmaceuticals, Inc. AMPH

Full chart Compare
Set alert

Price alert · AMPH

All alert types
28.12 USD +1.00 (+3.69%)

Nov 4, 2026, 2:42 PM EST

27.09 Day range 28.57
16.65 52-week range 29.52
YTD
+5.01%
1 year
+11.32%
Market cap
1.19B
Revenue (ttm)
730.02M
Profit margin
10.76%
EPS (ttm)
1.69
Shares out
42.54M
P/E ratio
16.62
Forward P/E
8.55
YTD return
+5.01%
1-year return
+11.32%
Volume
374.56K
Avg volume
468.38K
Open
27.49
Previous close
27.12
Day's range
27.09 – 28.57
52-week range
16.65 – 29.52
Beta
0.94
Analysts
Hold
Price target
22.50 (-20.0%)
Earnings date
Nov 5, 2026

2Y -22.43 (-44.34%)

2040Jan 25Jun 25Nov 25Apr 26Aug 2628.16

Key statistics

Enterprise value
1.55B
PEG ratio
0.00
Price / sales
1.58
Price / book
1.50
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
5.40%
Free cash flow
230.10M
Total cash
290.12M
Total debt
688.32M
Return on equity
10.30%
Short % of float
22.20%
50-day average
24.87
200-day average
22.25

Financials — quick view

All financials
AMPH Revenue — quarterly 183.90M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
AMPH Net income — quarterly 30.35M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
AMPH EPS — quarterly 0.69
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

AMPH recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 20260.859———
Aug 6, 2026Jun 30, 20260.620.91+0.29+46.77%
May 7, 2026Mar 31, 20260.700.42-0.28-40.00%
Feb 26, 2026Dec 31, 20250.9030.73-0.17-19.16%
Nov 6, 2025Sep 30, 20250.770.93+0.16+20.78%
Aug 7, 2025Jun 30, 20250.710.85+0.14+19.72%

Upgrades / downgrades

AMPH analyst upgrades and downgrades
DateFirmActionFromTo
Aug 18, 2026BarclaysmainEqual-WeightEqual-Weight
Aug 7, 2026Piper SandlermainNeutralNeutral
Aug 7, 2026Wells FargomainEqual-WeightEqual-Weight
Jun 29, 2026B of A SecuritiesdownNeutralUnderperform
Jun 3, 2026BarclaysmainEqual-WeightEqual-Weight
May 14, 2026Wells FargodownOverweightEqual-Weight

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States

News

Your note

Sign in to keep a note on AMPH — it syncs with the Stock Master app.

Insider holders

AMPH insider holders
InsiderRelationLatest transactionDateShares held
DEFLIN GAYLEDirectorStock Award(Grant)May 31, 202619,057
GERST DIANE G.DirectorStock Award(Grant)May 31, 202631,899
LEE HOWARD SDirectorStock Award(Grant)May 31, 2026159,350
LIAWATIDEWI YAKOBOfficer and DirectorStock Award(Grant)Mar 8, 2026125,384
PETERS WILLIAM JChief Financial OfficerSaleSep 20, 2026168,707
PETERSEN FLOYD FDirectorSaleDec 11, 202571,368

Institution ownership

AMPH institution ownership
Holder% heldSharesValueReported
Blackrock Inc.12.28%5,224,934141.70MJun 29, 2026
Dimensional Fund Advisors LP5.42%2,305,10762.51MJun 29, 2026
State Street Corporation3.86%1,642,12644.53MJun 29, 2026
Vanguard Capital Management LLC3.48%1,481,95240.19MJun 29, 2026
American Century Companies Inc2.77%1,176,62631.91MJun 29, 2026
Marshall Wace LLP2.51%1,066,32228.92MJun 29, 2026

Fund ownership

AMPH fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF4.40%1,873,13350.80MSep 29, 2026
American Century ETF Trust-Avantis U.S. Small Cap Value ETF3.06%1,303,43535.35MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.48%1,055,67628.63MJun 29, 2026
Capitol Series Trust-FullerThaler Behavioral Small-Cap Equity Fund2.12%902,73724.48MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.97%839,36622.76MSep 29, 2026
DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Small Cap Value Portfolio1.40%596,07716.17MJul 30, 2026